Vertex Pharma publishes kidney results as Vertex Pharma stock trades at EUR 469.45

Published on 10/26/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RAINIER cut proteinuria 52.00 percent at Week 36 on October 23, 2026. Vertex Pharma stock trades at EUR 469.45 on October 26, 2026.

Kidney program and key dates

Vertex Pharmaceuticals published RAINIER findings on October 23, 2026, including a 52.00 percent proteinuria reduction.
Povetacicept reduced proteinuria 49.80 percent versus placebo at Week 36.
Vertex Pharma stock traded at EUR 469.45 at 12:20 p.m. CEST at Lang & Schwarz on October 26, 2026.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin am Mikroskop im Labor — Vertex Pharma US92532F1003 dokumentiert eine Forscherin beim Mikroskopieren in dokumentarischer Schwarzweiß-Reportage-Optik im Labor, Illustration mit AI erstellt.

Vertex Pharma stock was trading at EUR 469.45 at Lang & Schwarz on October 26, 2026 at 12:20 p.m. CEST as the company advanced its kidney drug program. On October 23, 2026, Vertex Pharmaceuticals announced Phase 3 RAINIER results for povetacicept in IgA nephropathy, including a 52.00 percent reduction in proteinuria at Week 36.

Kidney data sharpen the pipeline

The pivotal trial delivered a 49.80 percent reduction versus placebo, according to Vertex Pharmaceuticals. The company said the therapy is administered at home through a low-volume autoinjector once every four weeks, while the trial continues toward a final analysis at two years.

The result gives Vertex a measurable development milestone beyond cystic fibrosis. The RAINIER study enrolled 605 adults, and the company said its findings support a biologics license application already accepted for accelerated review.

Three dates shape the story

On August 3, 2026, Vertex reported quarterly revenue of USD 3.33 billion, up 12.50 percent year over year, while adjusted earnings per share reached USD 4.73, according to MarketBeat. On September 1, 2026, the company completed its USD 10.00 billion acquisition of Crinetics Pharmaceuticals, as reported by Upside. The October 23, 2026 RAINIER release then added the 52.00 percent kidney trial result.

What does the kidney result add?

For investors, the important change is the potential breadth of Vertex's earnings base. Povetacicept targets IgA nephropathy, while related studies are also examining other immune-mediated diseases, and the four-week dosing preference reported in the release supports a practical administration profile.

Two dates now matter

Benzinga lists November 2, 2026 as the next quarterly earnings date. Vertex's release identifies November 30, 2026 as the PDUFA target action date for povetacicept.

Stock trades at a measured level

The euro quotation places the stock at EUR 469.45 during the regular Xetra perspective on October 26, 2026. The most important near-term test is whether the November clinical and earnings calendar can turn the kidney program into a broader commercial narrative.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.